Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing-remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
Introduction
Disease-modifying therapies (DMTs) are the mainstay of treatment for relapsing–remitting multiple sclerosis (RRMS). There is established evidence that DMTs are effective at reducing relapse rate and disease progression in RRMS, but there has been less consideration to the synthesis of MRI and neurocognitive outcomes, which play an increasingly important role in treatment decisions. The aim of this systematic review and network meta-analysis is to examine the relative efficacy, acceptability and tolerability of DMTs for RRMS, using MRI and neurocognitive outcomes.
Methods and analysis
We will search elec...
Source: BMJ Open - November 2, 2021 Category: General Medicine Authors: Lees, S., Dicker, M., Ku, J. E., Chaganti, V., Mew-Sum, M., Wang, N., Smith, A., Oldmeadow, C., Goon, W. L., Bevan, M., Lang, D., Hinwood, M. Tags: Open access, Neurology Source Type: research
Longitudinally Extensive Transverse Myelitis in Highly Active Relapsing-remitting Multiple Sclerosis
We describe a patient with highly active relapsing-remitting multiple sclerosis on interferon beta-1a who developed LETM after multiple relapses. (Source: Neurology India)
Source: Neurology India - October 30, 2021 Category: Neurology Authors: Chen Fei Ng Rabani Remli Hui Jan Tan Source Type: research
Comparing the outcomes of treatment with INF- β 1-a (interferon beta-1a) and IFN-β 1-b (interferon beta-1b) among COVID-19 inpatients
CONCLUSION: There was no significant difference between the two groups in terms of shortening the disease time, clinical improvements and other outcomes.PMID:34688151 | PMC:PMC8516800 | DOI:10.1016/j.intimp.2021.108241 (Source: International Immunopharmacology)
Source: International Immunopharmacology - October 23, 2021 Category: Allergy & Immunology Authors: Shahram Seyfi Kayvan Latifi Parviz Amri Male Mahmoud Sadeghi Haddad Zavareh Khadijeh Ezoji Mousa Mohammadnia-Afrozi Source Type: research
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med. 2021 Oct 18:S2213-2600(21)00384-2. doi: 10.1016/S2213-2600(21)00384-2. Online ahead of print.ABSTRACTBACKGROUND: Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a in combination with remdesivir compared with remdesivir alone in hospitalised patients with COVID-19.METHODS: We did a double-blind, randomised, placebo-controlled trial at 63 hospitals across five countries (Japan, Mexico, Singapore, South Korea, and the USA). Eligible patients were hospita...
Source: Respiratory Care - October 21, 2021 Category: Respiratory Medicine Authors: Andre C Kalil Aneesh K Mehta Thomas F Patterson Nathaniel Erdmann Carlos A Gomez Mamta K Jain Cameron R Wolfe Guillermo M Ruiz-Palacios Susan Kline Justino Regalado Pineda Anne F Luetkemeyer Michelle S Harkins Patrick E H Jackson Nicole M Iovine Victor F Source Type: research
Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report
Susac syndrome (SS) is characterized by the triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss. However, the diagnosis of SS remains difficult because the clinical triad r... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - September 30, 2021 Category: Opthalmology Authors: Joanna Roskal-Wa łek, Michał Biskup, Magdalena Dolecka-Ślusarczyk, Anita Rosołowska, Andrzej Jaroszyński and Dominik Odrobina Tags: Case report Source Type: research
Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis
Ann Agric Environ Med. 2021 Sep 16;28(3):372-377. doi: 10.26444/aaem/127062. Epub 2020 Sep 17.ABSTRACTINTRODUCTION: Multiple sclerosis (MS) is a disease of unknown etiology. Diagnosis of MS is primarily based on detection of myelin damage by magnetic resonance imaging (MRI) and classification of demyelination according to the McDonald Criteria. Cholecalciferol (vitamin D3) has been shown to affect the onset and progression of MS via its immunomodulating properties. The role of vitamin D in MS pathogenesis and treatment deserves further investigation, as there is sufficient evidence to suggest a correlation between vitamin ...
Source: Annals of Agricultural and Environmental Medicine : AAEM - September 24, 2021 Category: Environmental Health Authors: Faustyna Pi ędel Agata Rocka Miko łaj Piwek Patryk Piotr Jasielski V éronique Petit Konrad Rejdak Source Type: research
Correlation between vitamin D and alterations in MRI among patients with multiple sclerosis
Ann Agric Environ Med. 2021 Sep 16;28(3):372-377. doi: 10.26444/aaem/127062. Epub 2020 Sep 17.ABSTRACTINTRODUCTION: Multiple sclerosis (MS) is a disease of unknown etiology. Diagnosis of MS is primarily based on detection of myelin damage by magnetic resonance imaging (MRI) and classification of demyelination according to the McDonald Criteria. Cholecalciferol (vitamin D3) has been shown to affect the onset and progression of MS via its immunomodulating properties. The role of vitamin D in MS pathogenesis and treatment deserves further investigation, as there is sufficient evidence to suggest a correlation between vitamin ...
Source: Annals of Agricultural and Environmental Medicine : AAEM - September 24, 2021 Category: Environmental Health Authors: Faustyna Pi ędel Agata Rocka Miko łaj Piwek Patryk Piotr Jasielski V éronique Petit Konrad Rejdak Source Type: research
